Moderate Continuous and Modified High-Intensity Interval Training in Patients With Left Ventricular Assist Devices: The Prospective Train-the-LVAD Trial
Journal of Cardiac Failure · 2023-05 · 29 (5) · 841-848
DOI: 10.1016/j.cardfail.2023.01.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2023-05. Verfasst von Simon Wernhart und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, West German Heart and Vascular Center, Essen, G…. Hauptthemen laut MEDLINE: Heart Failure, High-Intensity Interval Training. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: High-intensity interval training (HIIT) of 4 minutes at 80%-90% of peak oxygen consumption (VO2peak) has been shown to be feasible in patients with left ventricular assist devices (LVADs). The effect of shorter bouts of HIIT, which reduce the anaerobic burden, has not been investigated compared to moderate continuous training (MCT). METHODS AND RESULTS: We conducted a prospective, monocentric study (NCT05121077) randomizing patients with LVADs into 20 minutes of MCT (n = 10) or short bouts (≤ 90 seconds) of HIIT (n = 10) following cardiopulmonary exercise testing at 50%-60% and 80%-90% of VO2peak. Each of the 18 supervised sessions (3×/week, t0-t1) included 10 minutes of strengthening training. The primary outcome was the increase of VO2peak in the 2 groups between t0 and t1. Secondary outcomes were changes in the 12-item Kansas City Cardiomyopathy Questionnaire, the 6-minute walk distance and the percentage of VO2peak at the first ventilatory threshold. VO2peak significantly increased with HIIT (13.0 ± 4.6mL/kg/min vs 14.6 ± 4.3mL/kg/min; P = 0.037), but not with MCT (11.8 ± 3.3mL/kg/min vs 13.1 ± 3.3mL/kg/min; P = 0.322), without between-group differences (P = 0.853). Secondary outcomes improved from t0-t1 in MCT and HIIT, without differences between the groups. CONCLUSIONS: Short bouts of HIIT are feasible, and they improved VO2peak and functional parameters in patients in this pilot prospective study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, West German Heart and Vascular Center, Essen, Germany. Electronic address: simon.wernhart@uk-essen.de.
- Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, West German Heart and Vascular Center, Essen, Germany.
- Department of Physiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Department of Thoracic and Cardiovascular Surgery,University Hospital Essen, University Duisburg-Essen, West German Heart- and Vascular Center, Essen, Germany.
Zitieren
APA
Wernhart, S., Oster, M., Schulze, M., Papathanasiou, M., Ruhparwar, A., Rassaf, T., & Luedike, P. (2023). Moderate Continuous and Modified High-Intensity Interval Training in Patients With Left Ventricular Assist Devices: The Prospective Train-the-LVAD Trial. Journal of Cardiac Failure, 29(5), 841-848. https://doi.org/10.1016/j.cardfail.2023.01.007
Vancouver
Wernhart S, Oster M, Schulze M, Papathanasiou M, Ruhparwar A, Rassaf T, et al. Moderate Continuous and Modified High-Intensity Interval Training in Patients With Left Ventricular Assist Devices: The Prospective Train-the-LVAD Trial. Journal of Cardiac Failure. 2023;29(5):841-848. doi:10.1016/j.cardfail.2023.01.007
BibTeX
@article{Wernhart2023,
author = {Wernhart, Simon and Oster, Marcel and Schulze, Martin and Papathanasiou, Maria and Ruhparwar, Arjang and Rassaf, Tienush and Luedike, Peter},
title = {Moderate Continuous and Modified High-Intensity Interval Training in Patients With Left Ventricular Assist Devices: The Prospective Train-the-LVAD Trial},
journal = {Journal of Cardiac Failure},
year = {2023},
volume = {29},
number = {5},
pages = {841--848},
doi = {10.1016/j.cardfail.2023.01.007}
}
EUVIMED